[Rosiglitazone--statistics for benefits and problems].
Hjelmesaeth
Jøran
J
Senter for sykelig overvekt i Helse Sør-Øst, Sykehuset Vestfold, 3103 Tønsberg. joran.hjelmeseth@siv.no
Røislien
Jo
J
D002318:Cardiovascular Diseases / Q000139:chemically induced; D003924:Diabetes Mellitus, Type 2 / Q000188:drug therapy; D006801:Humans; D007004:Hypoglycemic Agents / Q000009:adverse effects / Q000627:therapeutic use; D015201:Meta-Analysis as Topic; D016032:Randomized Controlled Trials as Topic; D012307:Risk Factors; D000077154:Rosiglitazone; D045162:Thiazolidinediones / Q000009:adverse effects / Q000627:therapeutic use
D007004:Hypoglycemic Agents; D045162:Thiazolidinediones; D000077154:Rosiglitazone